Tekcapital files patent for potential treatment in coronavirus patients
Belluscura and its research partner, Separation Design Group, have filed a patent on an oxygen enrichment device and system for treating acute respiratory distress (ARDS) which occurs in the most serious cases of the Coronavirus.
The patent application covers novel integrated portable extracorporeal oxygenation and carbon dioxide removal systems, the UK intellectual property investment group noted.
This ‘next-generation’ portable ECMO technology will be used to remove carbon dioxide from and diffuse oxygen into a patient's blood outside the body which allows the lungs time to recover.
Shares in Tekcapital were trading 6.19% higher at 5.15p during Monday trading.
Belluscura, of which Tekcapital owns a 18.9% interest in, is focused on developing novel oxygen-based treatment platforms that can be adapted and applied in a wide range of markets.
In this case, the portable ECMO technology will be offered in instances where oxygen therapy and ventilator support -- current primary treatments of the infection -- are rendered ineffective.
"We are pleased to see the additional progress of Belluscura as it continues to strengthen its intellectual property in the oxygen therapy space to help patients afflicted with acute respiratory distress caused by the Coronavirus, said Clifford Gross, Executive Chairman of Tekcapital.
This year, Belluscura will launch its first product, the X-PLOR™ portable oxygen concentrator, into the respiratory treatment field in order to treat chronic obstructive pulmonary disease.
Tekcapital added that Belluscura is likely to receive FDA clearance for their portable oxygen concentrator within the next 90 days.
Follow News & Updates from Tekcapital here:
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.